89bio
ETNB

$8.19

1.21%

Market Cap: $867M

About: 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Employees: 70

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

57% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 42

1.01% less ownership

Funds ownership: 105.37% [Q1] → 104.36% (-1.01%) [Q2]

3% less funds holding

Funds holding: 149 [Q1] → 144 (-5) [Q2]

20% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 25

28% less capital invested

Capital invested by funds: $1.15B [Q1] → $823M (-$323M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

89% less call options, than puts

Call options by funds: $1.24M | Put options by funds: $10.8M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

47%

upside

Avg. target

$30

271%

upside

High target

$53

547%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Cantor Fitzgerald Kristen Kluska 54% 1-year accuracy 54 / 100 met price target	254%upside $29	Overweight Reiterated	20 Sept 2024
Raymond James Steven Seedhouse 54% 1-year accuracy 13 / 24 met price target	547%upside $53	Strong Buy Maintained	6 Aug 2024
RBC Capital Brian Abrahams 51% 1-year accuracy 39 / 76 met price target	47%upside $12	Sector Perform Maintained	6 Aug 2024
HC Wainwright & Co. Ed Arce 44% 1-year accuracy 57 / 129 met price target	254%upside $29	Buy Reiterated	6 Aug 2024
Cantor Fitzgerald Kristen Kluska 54% 1-year accuracy 54 / 100 met price target	254%upside $29	Overweight Reiterated	1 Jul 2024

See Analyst Rankings

Financial journalist opinion

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company's common stock to one new employee (the “Inducement Grant”) on September 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company.

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,800 shares of the Company's common stock to two new employees and 350,000 shares of the Company's common stock to the newly-hired Chief Operating Officer, Francis Sarena (the “Inducement Grants”) on August 5, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc. has two phase 3 studies underway, known as ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, which are using pegozafermin to target F2 — F3 and F4 compensated cirrhosis MASH patients respectively. The promise of the two ongoing phase 3 ENLIGHTEN studies is that there was alignment gained with the FDA that each could use an interim analysis endpoint for potential Accelerated Approval. The global non-alcoholic steatohepatitis market is projected to reach $24.26 billion by 2028.

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio Appoints Francis Sarena as Chief Operating Officer

SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024.

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients–

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, July 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 125,000 shares of the Company's common stock to six new employees (the “Inducement Grants”) on July 9, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company's common stock to two new employees (the “Inducement Grants”) on June 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors Business Daily

Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.

Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin has the potential to tap into a large market and has been granted FDA Breakthrough Therapy designation for treating MASH with fibrosis.

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

See News Rankings